{{Drugbox
| Watchedfields = changed
| verifiedrevid = 448081332
| IUPAC_name = ''N''-[(2''S'',3''S'')-4-(4-chlorophenyl)-3-(3-cyanophenyl)-2-butanyl]-2-methyl-2-<nowiki/>{[5-(trifluoromethyl)-2-pyridinyl]oxy}propanamide
| image = Taranabant.png
| alt = Skeletal formula of taranabant
| width = 250
| image2 = Taranabant 3D spacefill.png
| alt2 = Space-filling model of the taranabant molecule

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  Investigational (failed)
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 701977-09-5
| ATC_prefix = A08
| ATC_suffix = AX
| PubChem = 11226090
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = X9U622S114
|  ChemSpiderID = 9401143

<!--Chemical data-->
| chemical_formula =  
| C=27 | H=25 | Cl=1 | F=3 | N=3 | O=2 
| molecular_weight = 515.95 g/mol
|  smiles = C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F
|  StdInChI = 1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1
|  StdInChIKey = QLYKJCMUNUWAGO-GAJHUEQPSA-N

}}

'''Taranabant''' (codenamed '''MK-0364''') is a [[cannabinoid receptor type 1]] [[inverse agonist]] that was investigated as a potential treatment for [[obesity]] due to its [[anorectic]] effects.<ref>Armstrong HE, Galka A, Lin LS, Lanza TJ Jr, Jewell JP, Shah SK, et al. "Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists." ''Bioorganic & Medicinal Chemistry Letters''. 2007 Apr 15;'''17'''(8):2184-7. {{PMID|17293109}}. {{doi|10.1016/j.bmcl.2007.01.087}}</ref><ref>Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, et al. "Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents." ''Journal of Pharmacology and Experimental Therapeutics''. 2007 Jun;'''321'''(3):1013-22. {{PMID|17327489}}. {{doi|10.1124/jpet.106.118737}}</ref> It was discovered by [[Merck & Co.]]

In October 2008, Merck has stopped its [[Clinical trials#Phase III|phase III]] [[clinical trials]] with the drugs due to high level of [[central nervous system|central]] side effects, mainly [[depression (mood)|depression]] and [[anxiety]].<ref name="urlMerck News Item">{{cite web |url=http://www.merck.com/newsroom/press_releases/research_and_development/2008_1002.html |title=Press release by Merck |work= |accessdate=October 2008}}</ref><ref name="pmid20157323">{{cite journal |vauthors=Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM |title=A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study |journal=International Journal of Obesity (2005) |volume=34 |issue=5 |pages=919–35 |date=May 2010 |pmid=20157323 |doi=10.1038/ijo.2010.21 |url=}}</ref><ref name="pmid20518807">{{cite journal |vauthors=Kipnes MS, Hollander P, Fujioka K, Gantz I, Seck T, Erondu N, Shentu Y, Lu K, Suryawanshi S, Chou M, Johnson-Levonas AO, Heymsfield SB, Shapiro D, Kaufman KD, Amatruda JM |title=A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes |journal=Diabetes, Obesity & Metabolism |volume=12 |issue=6 |pages=517–31 |date=June 2010 |pmid=20518807 |doi=10.1111/j.1463-1326.2009.01188.x |url=}}</ref><ref name="pmid20212496">{{cite journal |vauthors=Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanshi S, Jones ME, Johnson-Levonas AO, Heymsfield SB, Kaufman KD, Amatruda JM |title=A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study |journal=International Journal of Obesity (2005) |volume=34 |issue=8 |pages=1243–54 |date=August 2010 |pmid=20212496 |doi=10.1038/ijo.2010.38 |url=}}</ref>

== See also ==
* [[Cannabinoid receptor antagonist]]

==References==
{{Reflist}}

{{Anorectics}}
{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Anorectics]]
[[Category:Cannabinoids]]
[[Category:CB1 receptor antagonists]]
[[Category:Pyridines]]
[[Category:Nitriles]]
[[Category:Chloroarenes]]
[[Category:Trifluoromethyl compounds]]
[[Category:Carboxamides]]


{{cannabinoid-stub}}